<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484872</url>
  </required_header>
  <id_info>
    <org_study_id>ELCWP01501</org_study_id>
    <nct_id>NCT02484872</nct_id>
  </id_info>
  <brief_title>Has Inflammation a Significant Implication in Lung Cancer Evolution?</brief_title>
  <official_title>L'Inflammation A-t-elle Une Implication Significative Dans l'Ã©volution du Cancer Bronchique?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Lung Cancer Working Party</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Lung Cancer Working Party</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the
      Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of
      the study is to look at the prognostic and predictive value of inflammation during cancer
      evolution, on the risk of complications leading to ICU admission and the risk of death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood
      sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and
      in case of complication.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Measured from diagnosis until death or last date known to be alive, or at least 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications leading to emergency/ICU</measure>
    <time_frame>From inclusion until death, or a least 48 months</time_frame>
    <description>Recording any complication leading to consultation at the emergency department or admission into the intensive care unit</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>Lung neoplasms</arm_group_label>
    <description>Lung neoplasms irrespective of stage and histology</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sampling (serum)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed untreated lung neoplasms
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lung neoplasms irrespective of stage, histology

        Exclusion Criteria:

          -  Previously treated lung neoplasms

          -  A history of prior malignant tumour, except non-melanoma skin cancer or in situ
             carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free
             interval)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Pascale Meert, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Pascale Meert, MD, PhD</last_name>
    <phone>+32/2/5413191</phone>
    <email>ap.meert@bordet.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Leclercq, RN</last_name>
    <phone>+32/2/5413192</phone>
    <email>nathalie.leclercq@bordet.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Pascale Meert, MD, PhD</last_name>
      <phone>+32/2/5413191</phone>
      <email>ap.meert@bordet.be</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Leclercq, RN</last_name>
      <phone>+32/2/5413192</phone>
      <email>nathalie.leclercq@bordet.be</email>
    </contact_backup>
    <investigator>
      <last_name>Thierry Berghmans, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Pascale Meert, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Paul Sculier, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Glasgow score</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Emergency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

